The latest in the deals landscape in China has seen Wenzhou Kangninzg is exploring a secondary listing on the Shanghai bourse, while Rici Healthcare is reviving its Hong Kong IPO plans, even as the trade sale of Golden Meditechs stake in China Cord Blood Corporation is under threat.
End the Year with a Deal You Can’t Miss!
Subscribe now and save 40% on our premium subscription.
Enjoy unlimited access for a full year at just $199 (usual price $339).
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Offer valid for a limited time – don’t wait to unlock the insights that drive deal-making in Asia!
Subscribe nowAlready a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
